Stock listing
OTC:MYRX Myrexis Inc Stock
Follow Myrexis Inc into a list and get an email when it puts out news.
Share price · OTC:MYRX
$0.0008 USD 0.0000 (0.0%)
Close on Nov 19, 2026
- Day range
- $0.0008 – $0.0008 USDNov 19, 2026
- Market cap
- $27,583 USDAt the close on Nov 19, 2026 · price × 34.48M shares outstanding
- 52-week range
- $0.0003 – $0.0050 USDLowest and highest trades, Nov 20, 2025 – Nov 19, 2026
- Traded on an average day
- $1 USDMedian day 0 shares · 61 days with no trades · last 3 months, Aug 19, 2026 – Nov 19, 2026

Daily closes
Last 3 months, Aug 19, 2026 – Nov 19, 2026 · OTC:MYRX · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $0.0008 | 0.0000 | 0.0% | $0.0008 | $0.0008 | $0.0008 | 0 | |
| $0.0008 | 0.0000 | 0.0% | $0.0008 | $0.0008 | $0.0008 | 0 | |
| $0.0008 | 0.0000 | 0.0% | $0.0008 | $0.0008 | $0.0008 | 0 | |
| $0.0008 | 0.0000 | 0.0% | $0.0008 | $0.0008 | $0.0008 | 0 | |
| $0.0008 | 0.0000 | 0.0% | $0.0008 | $0.0008 | $0.0008 | 0 | |
| $0.0008 | 0.0000 | 0.0% | $0.0008 | $0.0008 | $0.0008 | 0 | |
| $0.0008 | 0.0000 | 0.0% | $0.0008 | $0.0008 | $0.0008 | 0 | |
| $0.0008 | 0.0000 | 0.0% | $0.0008 | $0.0008 | $0.0008 | 0 | |
| $0.0008 | 0.0000 | 0.0% | $0.0008 | $0.0008 | $0.0008 | 0 | |
| $0.0008 | 0.0000 | 0.0% | $0.0008 | $0.0008 | $0.0008 | 0 | |
| $0.0008 | 0.0000 | 0.0% | $0.0008 | $0.0008 | $0.0008 | 0 | |
| $0.0008 | 0.0000 | 0.0% | $0.0008 | $0.0008 | $0.0008 | 0 | |
| $0.0008 | 0.0000 | 0.0% | $0.0008 | $0.0008 | $0.0008 | 0 | |
| $0.0008 | 0.0000 | 0.0% | $0.0008 | $0.0008 | $0.0008 | 0 | |
| $0.0008 | 0.0000 | 0.0% | $0.0008 | $0.0008 | $0.0008 | 0 | |
| $0.0008 | 0.0000 | 0.0% | $0.0008 | $0.0008 | $0.0008 | 0 | |
| $0.0008 | 0.0000 | 0.0% | $0.0008 | $0.0008 | $0.0008 | 0 | |
| $0.0008 | 0.0000 | 0.0% | $0.0008 | $0.0008 | $0.0008 | 0 | |
| $0.0008 | 0.0000 | 0.0% | $0.0008 | $0.0008 | $0.0008 | 0 | |
| $0.0008 | 0.0000 | 0.0% | $0.0008 | $0.0008 | $0.0008 | 0 | |
| $0.0008 | 0.0000 | 0.0% | $0.0008 | $0.0008 | $0.0008 | 0 | |
| $0.0008 | 0.0000 | 0.0% | $0.0008 | $0.0008 | $0.0008 | 0 | |
| $0.0008 | 0.0000 | 0.0% | $0.0008 | $0.0008 | $0.0008 | 0 | |
| $0.0008 | 0.0000 | 0.0% | $0.0008 | $0.0008 | $0.0008 | 0 | |
| $0.0008 | 0.0000 | 0.0% | $0.0008 | $0.0008 | $0.0008 | 0 | |
| $0.0008 | 0.0000 | 0.0% | $0.0008 | $0.0008 | $0.0008 | 0 | |
| $0.0008 | 0.0000 | 0.0% | $0.0008 | $0.0008 | $0.0008 | 0 | |
| $0.0008 | 0.0000 | 0.0% | $0.0008 | $0.0008 | $0.0008 | 2,175 | |
| $0.0008 | 0.0000 | 0.0% | $0.0008 | $0.0008 | $0.0008 | 0 | |
| $0.0008 | 0.0000 | 0.0% | $0.0008 | $0.0008 | $0.0008 | 0 | |
| $0.0008 | 0.0000 | 0.0% | $0.0008 | $0.0008 | $0.0008 | 500 | |
| $0.0008 | 0.0000 | 0.0% | $0.0008 | $0.0008 | $0.0008 | 100 | |
| $0.0008 | 0.0000 | 0.0% | $0.0008 | $0.0008 | $0.0008 | 0 | |
| $0.0008 | 0.0000 | 0.0% | $0.0008 | $0.0008 | $0.0008 | 0 | |
| $0.0008 | 0.0000 | 0.0% | $0.0008 | $0.0008 | $0.0008 | 0 | |
| $0.0008 | 0.0000 | 0.0% | $0.0008 | $0.0008 | $0.0008 | 0 | |
| $0.0008 | 0.0000 | 0.0% | $0.0008 | $0.0008 | $0.0008 | 0 | |
| $0.0008 | 0.0000 | 0.0% | $0.0008 | $0.0008 | $0.0008 | 0 | |
| $0.0008 | 0.0000 | 0.0% | $0.0008 | $0.0008 | $0.0008 | 0 | |
| $0.0008 | 0.0000 | 0.0% | $0.0008 | $0.0008 | $0.0008 | 0 | |
| $0.0008 | 0.0000 | 0.0% | $0.0008 | $0.0008 | $0.0008 | 0 | |
| $0.0008 | 0.0000 | 0.0% | $0.0008 | $0.0008 | $0.0008 | 0 | |
| $0.0008 | 0.0000 | 0.0% | $0.0008 | $0.0008 | $0.0008 | 200 | |
| $0.0008 | 0.0000 | 0.0% | $0.0008 | $0.0008 | $0.0008 | 0 | |
| $0.0008 | 0.0000 | 0.0% | $0.0008 | $0.0008 | $0.0008 | 0 | |
| $0.0008 | 0.0000 | 0.0% | $0.0008 | $0.0008 | $0.0008 | 0 | |
| $0.0008 | 0.0000 | 0.0% | $0.0008 | $0.0008 | $0.0008 | 0 | |
| $0.0008 | 0.0000 | 0.0% | $0.0008 | $0.0008 | $0.0008 | 0 | |
| $0.0008 | 0.0000 | 0.0% | $0.0008 | $0.0008 | $0.0008 | 0 | |
| $0.0008 | 0.0000 | 0.0% | $0.0008 | $0.0008 | $0.0008 | 0 | |
| $0.0008 | 0.0000 | 0.0% | $0.0008 | $0.0008 | $0.0008 | 0 | |
| $0.0008 | 0.0000 | 0.0% | $0.0008 | $0.0008 | $0.0008 | 0 | |
| $0.0008 | 0.0000 | 0.0% | $0.0008 | $0.0008 | $0.0008 | 0 | |
| $0.0008 | 0.0000 | 0.0% | $0.0050 | $0.0050 | $0.0008 | 50,000 | |
| $0.0008 | 0.0000 | 0.0% | $0.0008 | $0.0008 | $0.0008 | 0 | |
| $0.0008 | 0.0000 | 0.0% | $0.0008 | $0.0008 | $0.0008 | 0 | |
| $0.0008 | 0.0000 | 0.0% | $0.0008 | $0.0008 | $0.0008 | 512 | |
| $0.0008 | 0.0000 | 0.0% | $0.0008 | $0.0008 | $0.0008 | 0 | |
| $0.0008 | 0.0000 | 0.0% | $0.0008 | $0.0008 | $0.0008 | 0 | |
| $0.0008 | 0.0000 | 0.0% | $0.0008 | $0.0008 | $0.0008 | 0 | |
| $0.0008 | 0.0000 | 0.0% | $0.0008 | $0.0008 | $0.0008 | 0 | |
| $0.0008 | 0.0000 | 0.0% | $0.0008 | $0.0008 | $0.0008 | 0 | |
| $0.0008 | 0.0000 | 0.0% | $0.0008 | $0.0008 | $0.0008 | 0 | |
| $0.0008 | 0.0000 | 0.0% | $0.0008 | $0.0008 | $0.0008 | 0 | |
| $0.0008 | 0.0000 | 0.0% | $0.0008 | $0.0008 | $0.0008 | 0 | |
| $0.0008 | 0.0000 | 0.0% | $0.0008 | $0.0008 | $0.0008 | 0 | |
| $0.0008 | 0.0000 | 0.0% | $0.0008 | $0.0008 | $0.0008 | 0 |
- Ticker
- OTC:MYRX
- Asset type
- Stock
- Exchange
- OTC
- Currency
- USD
Valuation
price Nov 19, 2026
- Enterprise value
- No statements on 6ix yet
- P/E
- No statements on 6ix yet
- EV/sales
- No statements on 6ix yet
- EV/EBITDA
- No statements on 6ix yet
- Price/book
- No statements on 6ix yet
- Gross margin
- No statements on 6ix yet
- Operating margin
- No statements on 6ix yet
- Net margin
- No statements on 6ix yet
- Debt to equity
- No statements on 6ix yet
- Beta vs S&P 500
- 0.03
Team and board
| Officer | Role |
|---|---|
| Jonathan Couchman | Chief Executive Officer and Chief Financial Officer |
Events
| Quarter | Results | Share move |
|---|---|---|
| Quarter to Dec 31, 2024 | Feb 7, 2025 | +14.3% |
| Quarter to Sep 30, 2024 | Nov 18, 2024 | −1.4% |
| Quarter to Jun 30, 2024 | Sep 6, 2024 | 0.0% |
| Quarter to Mar 31, 2024 | May 10, 2024 | 0.0% |
| Quarter to Dec 31, 2023 | Feb 9, 2024 | +13.6% |
| Quarter to Sep 30, 2023 | Nov 9, 2023 | 0.0% |
| Quarter to Jun 30, 2023 | Sep 8, 2023 | 0.0% |
| Quarter to Mar 31, 2023 | May 12, 2023 | 0.0% |
| Quarter to Dec 31, 2022 | Feb 10, 2023 | |
| Quarter to Sep 30, 2022 | Nov 10, 2022 |
All 17 quarters
| Quarter | Results | Share move |
|---|---|---|
| Quarter to Jun 30, 2022 | Sep 9, 2022 | |
| Quarter to Mar 31, 2022 | May 13, 2022 | |
| Quarter to Dec 31, 2021 | Feb 11, 2022 | |
| Quarter to Sep 30, 2021 | Nov 11, 2021 | 0.0% |
| Quarter to Jun 30, 2021 | Sep 10, 2021 | −1.8% |
| Quarter to Mar 31, 2021 | May 7, 2021 | 0.0% |
| Quarter to Dec 31, 2020 | Feb 12, 2021 | +6.7% |
Financials
Annual, in USD
Income statement
| Line | FY2013 | FY2012 | FY2011 | FY2010 | FY2009 | FY2008 |
|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 185.0K | 90.0K | 5.46M | 110.8M |
| Cost of revenue | 0 | 0 | 712.0K | 1.15M | 53.7M | 118.9M |
| Gross profit | 0 | 0 | 185.0K | 90.0K | 5.46M | 110.8M |
| Research and development | 465.0K | 14.2M | 22.3M | 28.2M | 54.6M | 121.5M |
| Selling, general and administrative | 10.7M | 17.6M | 17.2M | 21.1M | ||
| Operating income | -12.0M | -31.8M | -39.4M | -48.1M | -58.1M | -31.4M |
| Depreciation and amortization | 387.0K | 1.28M | 1.66M | 1.35M | 2.85M | 3.21M |
| EBITDA | -11.6M | -30.5M | -37.7M | -46.8M | -55.3M | -28.1M |
| Interest expense | 0 | 0 | 0 | 0 | 0 | 0 |
| Income before tax | -11.6M | -31.2M | -38.7M | -47.0M | -34.4M | |
| Income tax | -370.0K | -592.0K | -2.30M | -1.17M | 3.02M | |
| Net income | -11.6M | -31.2M | -38.7M | -47.0M | -58.1M | -34.4M |
| Earnings per share, basic | -0.39 | -1.18 | -1.52 | -1.91 | -2.42 | -1.43 |
Balance sheet
| Line | FY2013 | FY2012 | FY2011 | FY2010 | FY2009 | FY2008 |
|---|---|---|---|---|---|---|
| Cash and equivalents | 1.14M | 19.7M | 19.2M | 35.9M | 128.4M | |
| Short-term investments | 75.0K | 68.7M | 86.4M | 103.0M | 40.7M | |
| Receivables | 4.55M | |||||
| Current assets | 1.24M | 89.5M | 107.5M | 139.3M | 169.3M | 5.18M |
| Property, plant and equipment | 649.0K | 3.31M | 6.00M | 5.34M | 10.3M | |
| Total assets | 1.24M | 91.7M | 121.3M | 154.1M | 193.7M | 15.7M |
| Accounts payable | 74.0K | 197.0K | 197.0K | 1.21M | 14.2M | |
| Current liabilities | 74.0K | 2.28M | 3.31M | 4.25M | 4.58M | 46.6M |
| Total liabilities | 74.0K | 2.28M | 3.31M | 4.25M | 4.58M | 46.6M |
| Shareholders' equity | 1.16M | 89.4M | 118.0M | 149.9M | 189.1M | -30.8M |
| Shares outstanding | 29.9M | 26.4M | 25.5M | 24.5M | 24.0M | 24.0M |
Cash flow
| Line | FY2013 | FY2012 | FY2011 | FY2010 | FY2009 | FY2008 |
|---|---|---|---|---|---|---|
| Cash from operations | -13.0M | -27.8M | -33.5M | -40.4M | -60.7M | 12.2M |
| Capital spending | 0 | -55.0K | -93.0K | -2.13M | -375.0K | -2.33M |
| Free cash flow | -13.0M | -27.8M | -33.5M | -42.5M | -60.7M | 12.2M |
| Cash from investing | 71.3M | 27.1M | 14.8M | -54.4M | -7.38M | -2.55M |
| Cash from financing | -76.9M | 1.17M | 1.95M | 2.35M | 196.4M | -9.63M |
| Dividends paid | -78.6M | |||||
| Share buybacks | 1.63M | 1.17M | 1.95M | 2.34M | ||
| Change in cash | -18.6M | 518.0K | -16.7M | -92.5M | 128.4M |
Cap table
Built by 6ix from Myrexis Inc’s releases
- Common shares
- 34,479,051
- Fully diluted
- 34,479,051
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 34,479,051 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 34,479,051 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| David W. Gryska Other companies: Celcuity Inc. (Director · Since at least Oct 1, 2026); Definium Therapeutics, Inc. (Audit · Since at least Jun 21, 2023); Forte Biosciences, Inc. (Director · Since at least Jan 10, 2023); GW Pharmaceuticals plc (Director · Sep 9, 2020 – May 5, 2021 · Past); Incyte Corporation (Executive Vice President, CFO · Oct 31, 2014 – Jul 16, 2018 · Past); PDL BioPharma Inc (Director · Mar 6, 2014 – Dec 30, 2020 · Past); Argos Therapeutics Inc (Director · Feb 6, 2014 – Feb 6, 2014 · Past); Aerie Pharmaceuticals Inc. (Director · Oct 25, 2013 – Nov 21, 2022 · Past); Hyperion Therapeutics Inc (Director · Jul 25, 2012 – Apr 15, 2013 · Past); Celgene Corporation (Chief Financial Officer · Dec 6, 2006 – Jul 13, 2010 · Past); Seagen Inc (Director · Feb 14, 2006 – Dec 14, 2023 · Past) | Chief Operating Officer, Director · May 11, 2012 – May 11, 2012 · Past |
| Jason M. Aryeh Other companies: Lifecore Biomedical, Inc. (Director · Since at least Aug 15, 2024); Orchestra BioMed Holdings, Inc. (Director · Since at least Jan 26, 2023); Anebulo Pharmaceuticals, Inc. (Board Member · Since at least May 6, 2021); Ligand Pharmaceuticals Incorporated (Director · Since at least May 30, 2007); Immunomedics Inc (Director · Jan 8, 2017 – Jan 8, 2017 · Past); Aralez Pharmaceuticals Inc (Director · Feb 5, 2016 – May 19, 2017 · Past); Novelion Therapeutics Inc (Director · Jun 4, 2012 – May 15, 2017 · Past); Vaxart, Inc. (Director · May 18, 2007 – May 25, 2011 · Past) | Director · Oct 19, 2011 – Jun 18, 2012 · Past |
| Steven D Scheiwe Other companies: Mr. Cooper Group Inc (Director · Since at least Mar 19, 2012); F45 Training Holdings Inc. (Director · Feb 14, 2023 – Feb 14, 2023 · Past); Atlas Financial Holdings Inc (Director · Aug 25, 2022 – Jan 9, 2023 · Past); Verso Corporation (Director · Oct 21, 2016 – Oct 16, 2018 · Past); INNOVATE Corp. (Director · Aug 10, 2010 – Jan 15, 2014 · Past); Hancock Fabrics Inc (Director · Aug 1, 2008 – Aug 4, 2015 · Past); Movie Gallery Inc (Director · May 20, 2008 – Jun 11, 2008 · Past) | Director · Feb 13, 2013 – Feb 13, 2013 · Past |
| Dennis Langer Other companies: Quoin Pharmaceuticals. Ltd (Director · Since at least Jan 1, 2023); Ernexa Therapeutics Inc. (Director · May 1, 2021 – Dec 8, 2021 · Past); Pernix Therapeutics Holdings Inc (Director · Nov 4, 2016 – May 22, 2018 · Past); Delcath Systems, Inc. (Director · Dec 11, 2014 – Jun 10, 2015 · Past); Dicerna Pharmaceuticals Inc (Director · Sep 24, 2013 – Jun 20, 2019 · Past); Myriad Genetics, Inc. (Director · Dec 2, 2011 – Jun 30, 2022 · Past) | Director · Dec 8, 2011 – Dec 8, 2011 · Past |
| Michael C. Pearce Other companies: Journey Medical Corporation (Director · Since at least Jul 9, 2024); Enveric Biosciences, Inc. (Director · May 9, 2008 – May 9, 2008 · Past); Pernix Therapeutics Holdings Inc (President and CEO, Director · Sep 17, 2007 – May 10, 2013 · Past) | Director · Feb 13, 2013 – Feb 13, 2013 · Past |
| Richard B Brewer Other companies: Capricor Therapeutics, Inc. (Executive Chairman, Director · Jul 21, 2010 – Mar 30, 2012 · Past); Oruka Therapeutics, Inc. (Director · Jan 27, 2009 – Feb 10, 2012 · Past); Dendreon Corp (Director · Dec 6, 2006 – Jan 3, 2012 · Past) | President and CEO, Director · May 11, 2012 – May 11, 2012 · Past |
| Robert Forrester Other companies: Immunomedics Inc (Director · Jan 8, 2017 – Jan 8, 2017 · Past); Verastem, Inc. (President and CEO, Director · Jan 26, 2012 – Jan 3, 2019 · Past); EPIRUS Biopharmaceuticals Inc (EVP and COO, Director · May 14, 2007 – Dec 21, 2009 · Past) | Director · Nov 11, 2010 – Dec 8, 2011 · Past |
| John T. Henderson Other companies: Cytokinetics, Incorporated (Chairman · Since at least Feb 19, 2009); Myriad Genetics, Inc. (Director · Jan 6, 2006 – Dec 5, 2019 · Past) | Director · Nov 11, 2010 – Jan 18, 2013 · Past |
| Timothy R Franson Other companies: Paratek Pharmaceuticals Inc (Director · Jul 21, 2015 – Sep 21, 2023 · Past); Cidara Therapeutics Inc (Director · Apr 14, 2015 – Jun 22, 2023 · Past) | Director · Nov 11, 2010 – Dec 8, 2011 · Past |
| Adrian N Hobden Other companies: Myriad Genetics, Inc. (Pres. Myriad Pharmaceuticals · Feb 16, 2006 – Jun 8, 2009 · Past) | President and CEO, Director · Sep 24, 2010 – Sep 24, 2010 · Past |
All 14 people
| Person | Seat |
|---|---|
| Jonathan Couchman Other companies: Enzo Biochem Inc (Director · Nov 22, 2024 – Jan 16, 2025 · Past) | Chairman, President and CEO, Director · Jan 22, 2013 – Jan 22, 2013 · Past |
| W Wayne Laslie Other companies: Myriad Genetics, Inc. (Chief Operating Officer, MPI · Feb 16, 2006 – May 8, 2009 · Past) | Chief Operating Officer · Sep 24, 2010 – Sep 24, 2010 · Past |
| Andrea Kendell | Chief Financial Officer · Sep 6, 2011 – Sep 25, 2012 · Past |
| Andrew Gibbs | VP, General Counsel · Sep 24, 2010 – Sep 24, 2010 · Past |
Log in to ask 6ix AI your own questions about Myrexis Inc.